Get the Stockscreener App
8.14
0.97%
-0.08
After Hours:
8.14
Biocryst Pharmaceuticals Inc stock is traded at $8.14, with a volume of 5.40M.
It is down -0.97% in the last 24 hours and down -9.15% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.22
Open:
$8.215
24h Volume:
5.40M
Relative Volume:
1.23
Market Cap:
$1.70B
Revenue:
$503.49M
Net Income/Loss:
$-53.47M
P/E Ratio:
-31.31
EPS:
-0.26
Net Cash Flow:
$-26.89M
1W Performance:
-4.80%
1M Performance:
-9.15%
6M Performance:
+3.04%
1Y Performance:
+11.81%
1-Day Range:
$8.05
$8.325
1-Week Range:
$8.02
$8.635
52-Week Range:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.14 | 1.72B | 503.49M | -53.47M | -26.89M | -0.26 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Swing Trade Outlook For Every Investor - jammulinksnews.com
BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketPre Market Review For Consistent Profits - jammulinksnews.com
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - Yahoo Finance
BioCryst Pharmaceuticals announces leadership transition as CEO plans retirement - Investing.com Australia
BioCryst Pharmaceuticals announces leadership transition as CEO plans retirement By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Announces CEO Transition as Jon Stonehouse Plans Retirement and Charlie Gayer Appointed Successor - Quiver Quantitative
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - GlobeNewswire Inc.
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetPre Market Forecasts For 2025 - jammulinksnews.com
RSI Crosses Above 30 for BioCryst Pharmaceuticals Inc. — Reversal in SightGrowth Based Investment Plan Guidance Highlighted - beatles.ru
Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) To Breakeven Soon - simplywall.st
BioCryst Pharmaceuticals (BCRX) Plunges 5.38% on Upcoming Earnings, Pipeline Hurdles Weigh - AInvest
BioCryst Pharmaceuticals Inc. Sees Relief Buying After Extended DropValue Investing Picks With Stability Outlined - metal.it
Bullish Candlestick Pattern Forms in BioCryst Pharmaceuticals Inc.Trade Insight With Community Collaboration Supported - metal.it
Published on: 2025-07-29 08:08:08 - metal.it
Published on: 2025-07-29 05:16:52 - metal.it
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedBuild wealth with reliable stock picks - jammulinksnews.com
How does BioCryst Pharmaceuticals Inc. compare to its industry peersUnlock daily market insights for better decisions - jammulinksnews.com
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyDiscover stocks with explosive upside potential - jammulinksnews.com
New Product Launches: Will They Boost BioCryst Pharmaceuticals Inc. Stock in 2025AI Powered Stock Call - metal.it
How many analysts rate BioCryst Pharmaceuticals Inc. as a “Buy”Capitalize on momentum-driven investment opportunities - jammulinksnews.com
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStay ahead with daily expert stock picks - jammulinksnews.com
What are analysts’ price targets for BioCryst Pharmaceuticals Inc. in the next 12 monthsDiscover market opportunities others miss - jammulinksnews.com
Published on: 2025-07-27 20:51:34 - jammulinksnews.com
Can BioCryst Pharmaceuticals Inc. stock recover from recent declineSafe High Return Entry Points - metal.it
Will BioCryst Pharmaceuticals Inc. stock benefit from AI tech trendsLow Risk ROI Maximization - metal.it
What analysts say about BioCryst Pharmaceuticals Inc. stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
What drives BioCryst Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - PrintWeekIndia
Why BioCryst Pharmaceuticals Inc. stock is on top investor watchlistsBreakout stock performance - jammulinksnews.com
What institutions are buying BioCryst Pharmaceuticals Inc. stock nowExceptional ROI - jammulinksnews.com
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastExceptional portfolio growth - PrintWeekIndia
BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital By Investing.com - Investing.com Canada
BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital - Investing.com
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq
Best Momentum Stock to Buy for June 4th - MSN
BioCryst to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewswire
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree High-Return Strategy Alerts - jammulinksnews.com
BioCryst: ORLADEYO Powers Profitability Amidst Rising HAE Competition (NASDAQ:BCRX) - Seeking Alpha
BioCryst Pharmaceuticals to Announce Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Nasdaq
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):